Sunovion Pharmaceuticals Inc. today announced post-hoc analysis results of a positive Phase 3 placebo-controlled clinical study, as well as interim data from a long-term open-label extension study evaluating Latuda (lurasidone HCI) in children and adolescents (10 to 17 years of age) with major depressive episodes associated with bipolar I disorder (bipolar depression).
from Dementia Big http://ift.tt/2z0SbDk via alcoholic dementia
http://ift.tt/2idyAG1
No comments:
Post a Comment